NRX Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
NRXP$2.380.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $7,797 | $1,443 |
| Accounts receivable, net | 161 | — |
| Prepaid expense and other current assets | 934 | 1,859 |
| Total current assets | 8,892 | 3,302 |
| Investments | 397 | — |
| Furniture and equipment, net | 63 | 10 |
| Right-of-use assets, net | 414 | — |
| Right-of-use asset - related party, net | 219 | — |
| Intangible assets, net (provisional) | 925 | — |
| Goodwill (provisional) | 1,793 | — |
| Other assets | 253 | 339 |
| Total assets | $12,956 | $3,651 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $4,270 | $4,130 |
| Accrued and other current liabilities | 11,337 | 10,149 |
| Accrued clinical site costs | 351 | 379 |
| Convertible note payable and accrued interest, current | — | 1,246 |
| Insurance loan payable | — | 320 |
| Warrant liabilities | 12,304 | 5,639 |
| Lease liability, short term | 211 | — |
| Lease liability, short term - related party | 105 | — |
| Total current liabilities | 28,578 | 21,863 |
| Convertible note payable and accrued interest, long term | — | 5,011 |
| Lease liability, noncurrent | 199 | — |
| Lease liability, noncurrent - related party | 116 | — |
| Total liabilities | 28,893 | 26,874 |
| Commitments and Contingencies (Note 10) | ||
| Stockholders’ deficit: | ||
| Preferred stock, $0.001 par value, 50,000,000 shares authorized. | $— | $— |
| Series A convertible preferred stock, $0.001 par value, 12,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2025 and 2024 | — | — |
| Common Stock, $0.001 par value, 500,000,000 shares authorized; 31,734,333 and 14,591,505 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 32 | 15 |
| Additional paid-in capital | 290,926 | 255,035 |
| Accumulated deficit | (306,895) | (278,273) |
| Total stockholders’ deficit | (15,937) | (23,223) |
| Total liabilities and stockholders' deficit | $12,956 | $3,651 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.